BridgeBio Pharma, Inc. (BBIO)
Health Care · biotechnology · NASDAQ
BridgeBio is a portfolio-based biotech firm focused on translating genetic science into precision therapies for patients with severe genetic disorders.
What BridgeBio Pharma, Inc. does
BridgeBio Pharma is a commercial-stage biopharmaceutical company that utilizes a decentralized portfolio operating model to discover, develop, and deliver precision medicines for patients with genetic diseases. The company identifies, acquires, and advances product candidates through wholly-owned and controlled entities, currently marketing its lead drug, acoramidis (Attruby/Beyonttra), for transthyretin amyloidosis.
Themes: genetic diseases, precision medicine, transthyretin amyloidosis, rare disease therapeutics
Fundamentals
- Price$79.37 as of 2026-08-26 close
- Market cap$15.5B as of 2026-08-26
- 1-year return+62.4% 2025-08-26 close $48.87 → 2026-08-26 close $79.37
- P/En/a negative earnings
- Net margin-124.4% as of 2026-08-26
- Gross margin+95.1% as of 2026-08-26
- ROE-206.7% as of 2026-08-26
- Debt / equity8.27 as of 2026-08-26
- Revenue growth (YoY)+355.2% as of 2026-08-26
- Revenue CAGR (3y)+86.3% SEC XBRL
- Beta1.04 as of 2026-08-26
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How BBIO compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-26
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-26
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BBIO is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no valuation data.
Short-term score
54.2 #488 of 1,696 scored · #98 of 239 in Health Care
Catalysts 62nd: open-market insider buys in 90 days 37, the analyst consensus rating is unchanged since the prior reading; trend 60th: a "golden cross" — its 50-day average is above its 200-day; weakest is momentum 47th: MACD momentum is negative.
Left this list on 24 Aug 2026
- Left 24 Aug 2026: score 52.9, rank 105 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
- Entered 18 Aug 2026: first selection for this list at rank 2, score 68.2.
Scores as of 25 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which BBIO reported a dividend payment is FY2019, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2019 ratio would not describe BBIO today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2019) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How BridgeBio Pharma, Inc. looks technically
BridgeBio Pharma, Inc. (BBIO) is trading 8.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 402 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-07-08, breaking below its recent trading range. It is 15.0% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 8.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $79.44 | $79.44 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $73.26 | $73.26 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 85.65. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 402 trading days ago — a "golden cross", a bullish long-term signal | 402 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 24.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 43.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($78.13 to $89.49) — its "stochastic" reading is 11 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 11.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 27 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $93.42 | $93.42 |
|---|---|---|
| From the 52-week high | it is 15.0% below its 52-week high (its highest price of the past year) | -15.0% |
| Above the 52-week low | it is 69.6% above its 52-week low (its lowest price of the past year) | +69.6% |
| Below the 52-week high | it is 15.0% below its highest point of the past year | 15.0% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-07-08, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $93.42 (set on 2026-07-09) | $93.42 |
| Given back of the 52-week move | over the past year its closes ranged ($47.29 to $90.17), and it has given back roughly a quarter of its rise from last year’s low — 25% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $62.30 to $63.67. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 25.2% |
| From the all-time high | it is 15.0% below its all-time high | -15.0% |
| Nearest price level | it is trading 0.6% above a support level at $78.92 — a price it turned at 7 times since 2025-12-22, most recently on 2026-08-17. Since 2024-08-26 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.6% |
| All-time low | its lowest closing price on record is $4.98 (set on 2022-05-12) | $4.98 |
| Above the all-time low | it is 1493.8% above its all-time low | +1,494% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move | 6th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.67 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.67 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $78.66 and $85.23 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $78.66 – $81.95 – $85.23 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges above its 200-day average price (8.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.80× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-26 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Open gap | it gapped 3.0% above the previous close 54 sessions ago and has not traded back through the level it left behind at 65.48 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.0% |
| Gap filled | a 2.8% gap up opened on 2026-08-11 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 5 sessions in a row, a -5.46% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 5 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.2 percentage points (the stock lost 5.5% while the market gained 3.7%) | -9.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 15.1 percentage points (the stock gained 17.2% while the market gained 2.1%) | +15.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 6.3 percentage points (the stock gained 17.4% while the market gained 11.1%) | +6.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 43.7 percentage points (the stock gained 62.4% while the market gained 18.7%) | +43.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 6.2% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $73.89 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +7.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $82.23 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -3.5% |
Price levels it has turned at before
BBIO last closed at $79.37 on 2026-08-26. Since 2024-08-26 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $78.92 | Support | 0.6% below the last close | turned there 7 times · 2025-12-22 to 2026-08-17 |
| $85.42 | Resistance | 7.6% above the last close | turned there four times · 2026-02-12 to 2026-08-19 |
| $71.34 | Support | 10.1% below the last close | turned there twice · 2026-01-12 to 2026-05-22 |
| $69.89 | Support | 11.9% below the last close | turned there four times · 2025-10-29 to 2026-06-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $85.65.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $67.26 and $74.28 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $85.65.
This reading has stood for 1 trading day, since 2026-08-26.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · in a Bollinger Band volatility squeeze · beating the market · On a losing streak (5+ lower closes in a row) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 21 analysts
- Mean price target$108.43 range $80.00 – $157.00; median $108.00
Analyst estimates, as of 2026-08-25. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BBIO
- Consensus EPS estimate-$0.5827 next reporting period, as of 2026-08-25
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of significant operating losses and expectation of continued losses.","Reliance on the commercial success of a single product (acoramidis) to reach profitability.","Need for additional capital and potential for future dilution or debt-related constraints."]
What changed in the latest 10-Q
AI-assisted comparison of BBIO's 10-Q filed 2026-05-07 against the prior one filed 2025-10-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references audited consolidated financial statements for year ended December 31, 2025 filed February 24, 2026 (vs. December 31, 2024 filed February 20, 2025 in older filing)
- Newer filing states company is 'commercial-stage' vs. older filing's description of being 'a new type of biopharmaceutical company'
- Newer filing references acoramidis product by name 'Acoramidis' in Overview section (vs. 'our commercial product' phrasing in older filing)
- Newer filing adds: 'On March 30, 2026, we submitted our New Drug Application to the FDA for oral BBP-418 for the treatment of LGMD2I/R9'
- Newer filing discloses: 'For the three months ended March 31, 2026 and 2025, we incurred net losses of $166.6 million and $169.6 million, respectively'
- Newer filing adds: 'On May 6, 2026, our Board of Directors approved a stock repurchase program pursuant to which we may purchase up to $500.0 million of BridgeBio's outstanding common stock'
- Newer filing adds detailed disclosure of January 21, 2026 issuance of $632.5 million principal amount of 0.75% Convertible Senior Notes due 2033, net proceeds of $619.3 million, and repurchase of 1,081,825 shares for $82.5 million
- Removed:
- Older filing's extensive background description removed: 'BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials', description of founding in 2015, team experience, creation of 19 INDs, FDA approvals for three products, and work across 40+ disease states
- Older filing's detailed explanation of genetic disease focus and scientific advances rationale removed
- Older filing's disclosure: 'During the nine months ended September 30, 2025, we generated net product revenue of $216.4 million' is absent from newer filing (which covers three months ended March 31, 2026)
- Older filing's disclosure of nine-month net losses of $538.3 million and $276.0 million removed
- Older filing's detailed disclosure regarding June 27, 2025 Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and related KKR & Co. Inc. transaction removed
- Reworded:
- Older: 'our FDA approved product with in our wholly-owned subsidiaries' changed to Newer: 'acoramidis within our wholly-owned subsidiaries' (product name now explicit, grammar corrected)
- Older: 'royalty financing, sale of certain assets' changed to Newer: 'royalty monetization' (different characterization of funding source)
- Older: 'our commercialization strategy for acoramidis' changed to Newer: 'our commercialization strategy for Attruby and Beyonttra' (use of brand names instead of generic name)
- Notes:
- Newer filing text appears truncated at 'On Ju' suggesting incomplete source document
- Comparison is between different quarterly periods (three months ended March 31, 2026 vs. nine months ended September 30, 2025), which accounts for some differences in reported metrics
- Older filing's lengthy Royalty Purchase Agreement disclosure is incomplete in the source provided ('Eidos sold to the Royalty Agreement Purchasers certain of Eidos' right to' text cuts off)
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 31 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 8 sells ($4M) — 2 selling insiders
- Last 90 days0 buys · 31 sells ($33M) — 5 selling insiders
- Last 180 days0 buys · 63 sells ($48M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-19. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BBIO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 7 matched disclosures for BBIO from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding BBIO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 37,343,736
- Reported value $2,773,145,830
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BBIO had 23,342,623 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BBIO had 11.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.5 days to cover at the same settlement.
- Reported short interest (shares) 23,342,623
- Short interest (% of shares outstanding) 11.9%
- Prior settlement (shares) 25,750,649
- Reported change -9.35%
- Days to cover (reported) 11.5
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BBIO vs…
BridgeBio Pharma, Inc. is found in…
BBIO ranks in…
Frequently asked questions
What does BridgeBio Pharma, Inc. (BBIO) do?
BridgeBio Pharma is a commercial-stage biopharmaceutical company that utilizes a decentralized portfolio operating model to discover, develop, and deliver precision medicines for patients with genetic diseases. The company identifies, acquires, and advances product candidates through wholly-owned and controlled entities, currently marketing its lead drug, acoramidis (Attruby/Beyonttra), for transthyretin amyloidosis.
What sector is BridgeBio Pharma, Inc. (BBIO) in?
BridgeBio Pharma, Inc. (BBIO) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are BridgeBio Pharma, Inc.'s (BBIO) competitors?
Notable peers of BridgeBio Pharma, Inc. (BBIO) include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Pfizer and AstraZeneca. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in BBIO?
Yes — we hold 7 matched STOCK Act disclosures for BBIO from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is BridgeBio Pharma, Inc. (BBIO) overbought or oversold right now?
BridgeBio Pharma, Inc. (BBIO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BBIO come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.